No abstract

No abstract

Purpose Evaluation of therapeutic efficacy in dry AMD patients using 3DComputer‐automated Threshold Amsler Grid testing (3D‐CTAG; Fink &Sadun, 2004). Methods Dry AMD patients (n=87, 174 eyes). Group#1 (n=29): 200 mg Docosahexaenoic Acid (DHA) and 300 mg Eicosapentaenoic Acid (EPA). Group #2 (n=29): Lutein (12 mg) and Zeaxanthin (0,5 mg). Controls (n=29). 3D‐CTAG testing after 3 months of treatment.Indices: number of VF defects per eye (ND),lowest perceivablecontrast level (CL), absolute volume lost (AVL), VF volume lost relative to hill‐of‐vision (VLRH). Results Group#1: ND=0,31±0,54 (before) down to 0,16±0,37(after treatment); CL=12,31±8,03% down to 10,9±7,21%; VLRH=1,2±1,14% down to 0,26±0,52%.Group#2: ND=0,29±0,5 down to 0,21±0,41; CL=11,72±12,79% down to 9,66±10,2%; VLRH=1,01±0,88% down to 0,68±1,14%. Controls: ND=0,29±0,5 up to 0,34±0,51; CL=13,79±8,65% up to 14,38±10,38%; VLRH=0,93±0,9% up to 1,22±1,21%. Conclusion We demonstrated with 3D‐CTAG a decrease of VLRH of 0,94% (p=0,01) in group#1 after 3 months DHA/EPA treatment compared to 0,33% (p=0,05) in group#2, and an increase of VLRH of 0,29% (p=0,01) in the controls. This seems to indicate that DHA/EPA treatment of dry AMD may be more effective than Lutein‐Zeaxanthin therapy. Commercial interest

Purpose To detect recurrence of macular edema inwet AMD patients after anti‐VEGF treatment using 3D‐Computer‐automated Threshold Amsler Grid testing (3D‐CTAG; Fink &Sadun, 2004). Methods Wet AMD patients (n=10, 11 eyes) 6 months after 3 injections of Ranibizumab (Lucentis, Novartis). Group #1(n=5, 6 eyes): norecurrence. Group #2 (n=5, 5 eyes): recurrence confirmed by OCT. Indices: # of VF defects per eye (ND); lowest perceivable contrast level (CL); VF volume lost relative to hill‐of‐vision (VLRH); lost area grade (LAG): [scotoma area at lowest tested contrast sensitivity level/scotoma area at highest tested contrast sensitivity level]×scotoma depth (%). Results Group #1:Visus=0,43±0,18logMAR; ND=0,67±1,2; CL=10±7,04%; VLRH=2,1±3,97%; LAG=150,92±341,35%. Group #2:Visus=0,51±0,49logMAR; ND=1,4±0,55; CL=38,8±12,03%; VLRH=15,18±10,56%; LAG=32,13±20,13%. Conclusion In group #2 3D‐CTAG revealed scotomas typical for macular edema: VLRH=15,18±10,56% compared to 2,1±3,97% (p=0,05) in group #1 and LAG=32,13±20,13% compared to 150,92±341,35% (p=0,05) in group #1. Observed functional disorders show that 3‐fold injection of Ranibizumab, adopted as the standard, appears to be insufficient in 45,45% of the cases. 3D‐CTAG may be an effective method for self‐monitoring the recurrence of macular edema in wet AMD patients. Commercial interest

No abstract